| 1 | action | 12,158 |
| 2 | asylum | 40 |
| 3 | pleiotropy | 25 |
| 4 | coevolution | 20 |
| 5 | coloproctology | 15 |
| 6 | if-then | 14 |
| 7 | moralization | 11 |
| 8 | cr/kg | 9 |
| 9 | masculinities | 9 |
| 10 | ca/kg | 8 |
| 11 | professionalization | 8 |
| 12 | self-handicapping | 8 |
| 13 | successors | 8 |
| 14 | cdsss/kmss | 7 |
| 15 | mir-124a | 7 |
| 16 | self-estimates | 7 |
| 17 | cancer-quality | 6 |
| 18 | chemoprotectants | 6 |
| 19 | chronomedicine | 6 |
| 20 | demicellization | 6 |
| 21 | fpss | 5 |
| 22 | half-metallicity | 5 |
| 23 | self-complexity | 5 |
| 24 | sucram/t | 5 |
| 25 | test-treat | 5 |
| 26 | α'-martensite | 5 |
| 27 | 5months | 4 |
| 28 | alhavi | 4 |
| 29 | constipation-quality | 4 |
| 30 | escorts | 4 |
| 31 | nano-scaling | 4 |
| 32 | nanopesticides | 4 |
| 33 | non-cessation | 4 |
| 34 | partograms | 4 |
| 35 | rebate | 4 |
| 36 | tralpha1 | 4 |
| 37 | 3d-imaging | 3 |
| 38 | angiomyxoma | 3 |
| 39 | ast/kg | 3 |
| 40 | baceo3 | 3 |
| 41 | co2-baths | 3 |
| 42 | effect.we | 3 |
| 43 | evolutionism | 3 |
| 44 | fear-relevance | 3 |
| 45 | genuineness | 3 |
| 46 | gpt2p | 3 |
| 47 | leucophores | 3 |
| 48 | livopo4 | 3 |
| 49 | mechanization | 3 |
| 50 | microvacuoles | 3 |
| 51 | multidifferentiation | 3 |
| 52 | nondiagnosis | 3 |
| 53 | pf-3893787 | 3 |
| 54 | phip/μmol | 3 |
| 55 | ro4607381 | 3 |
| 56 | rrss | 3 |
| 57 | super-hydration | 3 |
| 58 | thr/kg | 3 |
| 59 | tonifying-kidney | 3 |
| 60 | unc-45b | 3 |
| 61 | vabâ | 3 |
| 62 | 27-oh | 2 |
| 63 | 3-aryloxindoles | 2 |
| 64 | 4.2μm | 2 |
| 65 | 5'-deletions | 2 |
| 66 | 7s/kg | 2 |
| 67 | 8-sessions | 2 |
| 68 | aas-use | 2 |
| 69 | activty | 2 |
| 70 | acwy-tt+mmrv | 2 |
| 71 | al/ca | 2 |
| 72 | alkylglycerols | 2 |
| 73 | allopurinol/kg | 2 |
| 74 | asparaginate | 2 |
| 75 | bias.none | 2 |
| 76 | bio-responses | 2 |
| 77 | bleomycine | 2 |
| 78 | coffins | 2 |
| 79 | complications.comparison | 2 |
| 80 | cranberry-proanthocyandins | 2 |
| 81 | dosrs-dost/devrs-rv2027c | 2 |
| 82 | drug-sparing | 2 |
| 83 | enzyme/kg | 2 |
| 84 | ep-cam-expression | 2 |
| 85 | follow-up.this | 2 |
| 86 | gastro/duodenojejunostomy | 2 |
| 87 | hiv-pis | 2 |
| 88 | ifn-gamma1b | 2 |
| 89 | immunoreceptors | 2 |
| 90 | incursions | 2 |
| 91 | interim-analysis | 2 |
| 92 | intersexuality | 2 |
| 93 | iridologists | 2 |
| 94 | joven | 2 |
| 95 | lbw242 | 2 |
| 96 | limb-loss | 2 |
| 97 | lps/kg | 2 |
| 98 | massage/aromatherapy | 2 |
| 99 | metallo-enzymes | 2 |
| 100 | mg2+/kg | 2 |
| 101 | micro-foci | 2 |
| 102 | non-comparability | 2 |
| 103 | nonlocality | 2 |
| 104 | obstruction/reflux | 2 |
| 105 | over-inhibition | 2 |
| 106 | photopenia | 2 |
| 107 | products/procedures | 2 |
| 108 | punch-biopsies | 2 |
| 109 | pyrazolones | 2 |
| 110 | quercetin/kg | 2 |
| 111 | radicalism | 2 |
| 112 | re-referrals | 2 |
| 113 | receiver/stimulator | 2 |
| 114 | recitations | 2 |
| 115 | removal-area | 2 |
| 116 | revenue-generating | 2 |
| 117 | rpl-1980 | 2 |
| 118 | sb90-70 | 2 |
| 119 | science/web | 2 |
| 120 | self-potentiation | 2 |
| 121 | shreds | 2 |
| 122 | single-myoma-removal | 2 |
| 123 | spliced-mrna | 2 |
| 124 | swiftlets | 2 |
| 125 | tetrahydropteridines | 2 |
| 126 | th2-cytokines | 2 |
| 127 | thereto | 2 |
| 128 | tremors/shaking | 2 |
| 129 | triamcinolone-bevacizumab | 2 |
| 130 | uv-tolerance | 2 |
| 131 | w-nps | 2 |
| 132 | y783 | 2 |
| 133 | year-of-publication | 2 |
| 134 | δpepn | 2 |
| 135 | η≈0.35 | 2 |
| 136 | 'clearance | 1 |
| 137 | 'schemas | 1 |
| 138 | /diagnosis | 1 |
| 139 | 0.030/cm3 | 1 |
| 140 | 0.05mg/g | 1 |
| 141 | 0.076-7.6ng/ml | 1 |
| 142 | 0.1-1mg | 1 |
| 143 | 0.15g/l | 1 |
| 144 | 0.2491 | 1 |
| 145 | 0.521μg | 1 |
| 146 | 0.54/specificity | 1 |
| 147 | 0.590.validation | 1 |
| 148 | 0.5ml/min | 1 |
| 149 | 0.78:1 | 1 |
| 150 | 1,3-cyclohexadiones | 1 |
| 151 | 1,4-benzodiazepines | 1 |
| 152 | 1-32ng/ml | 1 |
| 153 | 1-me-d-trp | 1 |
| 154 | 1.26w/g | 1 |
| 155 | 1.5ml | 1 |
| 156 | 1.6g/d | 1 |
| 157 | 1/9-th | 1 |
| 158 | 10,000u | 1 |
| 159 | 1000uh | 1 |
| 160 | 11cycles | 1 |
| 161 | 11q13q21 | 1 |
| 162 | 12l/g | 1 |
| 163 | 13,328 | 1 |
| 164 | 14c-hdl | 1 |
| 165 | 17-hydroxycorticoids | 1 |
| 166 | 17β-reduction | 1 |
| 167 | 1mg/g | 1 |
| 168 | 2,720 | 1 |
| 169 | 2,992 | 1 |
| 170 | 2-fluorobenzaldehyde | 1 |
| 171 | 2.3/5 | 1 |
| 172 | 214.6-384.8mbq | 1 |
| 173 | 26.4±3.1 | 1 |
| 174 | 299g/kg | 1 |
| 175 | 3,7-β-o-diglucosides | 1 |
| 176 | 3-br-pa | 1 |
| 177 | 3-halo-derivatives | 1 |
| 178 | 3-methyl-1-phenylpyrazole | 1 |
| 179 | 3-methylcarbazoles | 1 |
| 180 | 3.92ev | 1 |
| 181 | 30g/day | 1 |
| 182 | 30iu | 1 |
| 183 | 35ml/kg/h | 1 |
| 184 | 3d-crt/imrt | 1 |
| 185 | 3d-motion | 1 |
| 186 | 4-chloro-6-methyl | 1 |
| 187 | 4.6-1.52 | 1 |
| 188 | 4.76±0.44 | 1 |
| 189 | 42-months | 1 |
| 190 | 43g | 1 |
| 191 | 46nt | 1 |
| 192 | 5-cis-lycopene | 1 |
| 193 | 5.3g | 1 |
| 194 | 50p/unit | 1 |
| 195 | 532~nm | 1 |
| 196 | 5`utr | 1 |
| 197 | 6-cycles | 1 |
| 198 | 78gy | 1 |
| 199 | 8,14-dihydroxy-efv | 1 |
| 200 | 80±21g | 1 |
| 201 | 90°c/h | 1 |
| 202 | 92.3kg | 1 |
| 203 | aa21-40aa141-160 | 1 |
| 204 | abruptness | 1 |
| 205 | accordances | 1 |
| 206 | actg076 | 1 |
| 207 | action-antagonism | 1 |
| 208 | action-restoration | 1 |
| 209 | activation/duration | 1 |
| 210 | active-site-cyssh | 1 |
| 211 | adequate-duration | 1 |
| 212 | administration/management | 1 |
| 213 | age-effect | 1 |
| 214 | age.meta-analysis | 1 |
| 215 | ahistory | 1 |
| 216 | ai-use | 1 |
| 217 | ailin | 1 |
| 218 | air-sampling | 1 |
| 219 | ala-272 | 1 |
| 220 | albumin/l | 1 |
| 221 | alginate/calcium | 1 |
| 222 | allspice/kg | 1 |
| 223 | ampliation | 1 |
| 224 | ampula | 1 |
| 225 | anxyolitics | 1 |
| 226 | as-fast-as-you-can | 1 |
| 227 | atheroregression | 1 |
| 228 | attachment/detachment | 1 |
| 229 | attestation | 1 |
| 230 | autism-or | 1 |
| 231 | autoflora | 1 |
| 232 | bacteria/l | 1 |
| 233 | baicalin+berberine | 1 |
| 234 | baromemteosensivity | 1 |
| 235 | base-stocks | 1 |
| 236 | bb1-10 | 1 |
| 237 | bb1-4 | 1 |
| 238 | bb3-12 | 1 |
| 239 | bep-treatment | 1 |
| 240 | beta-mangostin | 1 |
| 241 | bevacizumab/5-fu/lv | 1 |
| 242 | bi-nucleation | 1 |
| 243 | bi-products | 1 |
| 244 | bias.meta-analysis | 1 |
| 245 | bias.quality | 1 |
| 246 | bias.studies | 1 |
| 247 | binding-release | 1 |
| 248 | biodisesl | 1 |
| 249 | biogenicity | 1 |
| 250 | bioisosters | 1 |
| 251 | bisphosphontes | 1 |
| 252 | blinding.none | 1 |
| 253 | bortezomib-mp | 1 |
| 254 | bowstring | 1 |
| 255 | ca2+/atpase | 1 |
| 256 | cafu/kg | 1 |
| 257 | calliphorinae | 1 |
| 258 | capecitabine/rt | 1 |
| 259 | carabanchel | 1 |
| 260 | care/types | 1 |
| 261 | casemanagement | 1 |
| 262 | cd45ra/ccr7 | 1 |
| 263 | chicory/ton | 1 |
| 264 | chlorambucil-rituximab | 1 |
| 265 | chlortetracycline/kg | 1 |
| 266 | cholecysto-choledocholi-thiasis | 1 |
| 267 | cinocardioangiograms | 1 |
| 268 | ciprofloxacin-tinidazole | 1 |
| 269 | cisplatin/m2 | 1 |
| 270 | cocarettes | 1 |
| 271 | cocoa-flavanols | 1 |
| 272 | cocoa/chocolate | 1 |
| 273 | coextraction | 1 |
| 274 | cografting | 1 |
| 275 | colonizaion | 1 |
| 276 | concretes | 1 |
| 277 | consulting-cum-dispensing | 1 |
| 278 | corn/kg | 1 |
| 279 | corticorteroids | 1 |
| 280 | corticosteroides | 1 |
| 281 | cpimpdh·imp·8k | 1 |
| 282 | cr-c60 | 1 |
| 283 | crmn/ctm | 1 |
| 284 | cross-bracing | 1 |
| 285 | crotonaldehyde/kg | 1 |
| 286 | crowders | 1 |
| 287 | ct/kg | 1 |
| 288 | cuspules | 1 |
| 289 | cys-40 | 1 |
| 290 | d-isomeres | 1 |
| 291 | dads/kg | 1 |
| 292 | darwinism | 1 |
| 293 | de-icing | 1 |
| 294 | deagglomeration | 1 |
| 295 | decelerator/extensor | 1 |
| 296 | dehiscence/necrosis | 1 |
| 297 | demands/deliveries | 1 |
| 298 | demophobia | 1 |
| 299 | dhule | 1 |
| 300 | di-allyl-ation | 1 |
| 301 | diachrome/kg | 1 |
| 302 | dialysis.this | 1 |
| 303 | diatrofen | 1 |
| 304 | dihydrobenzothiepinones | 1 |
| 305 | diveticula | 1 |
| 306 | dmpa-subcutaneous | 1 |
| 307 | duration/frequency | 1 |
| 308 | dys-synchronization | 1 |
| 309 | e-liquids/e-juices | 1 |
| 310 | e2-cypionate | 1 |
| 311 | ecg/bnp | 1 |
| 312 | ectomycorrhizae | 1 |
| 313 | egcg/kg | 1 |
| 314 | egfr/erbb2 | 1 |
| 315 | electro-pathophysiology | 1 |
| 316 | embriopathy | 1 |
| 317 | eml1 | 1 |
| 318 | enchantment | 1 |
| 319 | endothermy | 1 |
| 320 | ensurance | 1 |
| 321 | enzyme/g | 1 |
| 322 | epidydimitis | 1 |
| 323 | epilepsy/absence | 1 |
| 324 | erythromycylamine | 1 |
| 325 | estrification | 1 |
| 326 | estrogen/er | 1 |
| 327 | etoposide/m2 | 1 |
| 328 | evidence/opinion | 1 |
| 329 | exceedences | 1 |
| 330 | eximerization | 1 |
| 331 | expectancy-manipulation | 1 |
| 332 | exposure-that | 1 |
| 333 | extracts.based | 1 |
| 334 | falkenberg | 1 |
| 335 | falling.there | 1 |
| 336 | falls.eighteen | 1 |
| 337 | fdft1 | 1 |
| 338 | fever≥38.0°c | 1 |
| 339 | fexofenadine.this | 1 |
| 340 | fine-groupings | 1 |
| 341 | flight/time | 1 |
| 342 | fluid-responsiveness | 1 |
| 343 | fluid/vapor | 1 |
| 344 | fncs | 1 |
| 345 | formation/disappearance | 1 |
| 346 | frewuency | 1 |
| 347 | friars | 1 |
| 348 | fruchaud | 1 |
| 349 | funding/conflict | 1 |
| 350 | gal021/placebo | 1 |
| 351 | genistein/kg | 1 |
| 352 | genistein•kg | 1 |
| 353 | gh/igfs | 1 |
| 354 | giardisis | 1 |
| 355 | glp-2/kg | 1 |
| 356 | growth/day | 1 |
| 357 | guilt/lack | 1 |
| 358 | h-13 | 1 |
| 359 | hachimi-jio-gan/day/200g | 1 |
| 360 | hav-igg | 1 |
| 361 | health-care-providers | 1 |
| 362 | heat-fire | 1 |
| 363 | heptamers | 1 |
| 364 | herbs-change | 1 |
| 365 | hesperidin/kg | 1 |
| 366 | hesperidin•kg | 1 |
| 367 | heterarchy | 1 |
| 368 | hexacarbonyl | 1 |
| 369 | high-grade/cancer | 1 |
| 370 | hippocampal-tnf | 1 |
| 371 | his337 | 1 |
| 372 | homocysteinaemia | 1 |
| 373 | homogeny | 1 |
| 374 | hotter-than-normal | 1 |
| 375 | hsp20-overexpression | 1 |
| 376 | hunault | 1 |
| 377 | hymexozol | 1 |
| 378 | hyper-activity/hyper-synchrony | 1 |
| 379 | hyperadrenergism | 1 |
| 380 | hyperalgesia/length | 1 |
| 381 | hypertonocity | 1 |
| 382 | hypocholesterolaemia | 1 |
| 383 | hyposensitizations | 1 |
| 384 | id/ida | 1 |
| 385 | ignificance | 1 |
| 386 | iiia-cp/cpps | 1 |
| 387 | il-22/il-34 | 1 |
| 388 | ilkpa | 1 |
| 389 | ill-treatment | 1 |
| 390 | implementation.direction | 1 |
| 391 | imprecision.two | 1 |
| 392 | inducers/inhibitors | 1 |
| 393 | infection-three | 1 |
| 394 | infectons | 1 |
| 395 | inhalation-technique | 1 |
| 396 | inner-accumulation | 1 |
| 397 | inputs-mechanism-outputs | 1 |
| 398 | interfusion | 1 |
| 399 | intraklassen-correlations | 1 |
| 400 | inverse-weighting | 1 |
| 401 | influence | 1 |
| 402 | ipsrt-regulation | 1 |
| 403 | iso-effectivity | 1 |
| 404 | isogeny | 1 |
| 405 | isolation/industrialization | 1 |
| 406 | it.it | 1 |
| 407 | jiayou | 1 |
| 408 | jukovsky | 1 |
| 409 | kr23 | 1 |
| 410 | lactonazole | 1 |
| 411 | ldl-c-reduction | 1 |
| 412 | leaded-petrol | 1 |
| 413 | life.all | 1 |
| 414 | life.most | 1 |
| 415 | life/activities | 1 |
| 416 | ligation/division | 1 |
| 417 | light-dependence | 1 |
| 418 | load-volume | 1 |
| 419 | louvain | 1 |
| 420 | lp229v | 1 |
| 421 | macrocyclizations | 1 |
| 422 | manualisation | 1 |
| 423 | melamine/kg | 1 |
| 424 | methylphenidate/placebo | 1 |
| 425 | mg277 | 1 |
| 426 | micro-veins | 1 |
| 427 | microagglutination | 1 |
| 428 | microinjuries | 1 |
| 429 | mir-124-5p | 1 |
| 430 | mir-7a | 1 |
| 431 | miscegenation | 1 |
| 432 | misdetections | 1 |
| 433 | mono-instead | 1 |
| 434 | monothio-1,3-diketones | 1 |
| 435 | morphine+50mg | 1 |
| 436 | mpt/mps | 1 |
| 437 | mri-features | 1 |
| 438 | multi-data | 1 |
| 439 | multitudiness | 1 |
| 440 | mutagenesity | 1 |
| 441 | mvc1 | 1 |
| 442 | mxcxxc | 1 |
| 443 | n-disubstituents | 1 |
| 444 | nad3 | 1 |
| 445 | natriuria | 1 |
| 446 | nbcl5 | 1 |
| 447 | needles/dislike | 1 |
| 448 | neuexin-3 | 1 |
| 449 | news-impact | 1 |
| 450 | nh3/min/mg | 1 |
| 451 | nile-delta | 1 |
| 452 | nitrites/g | 1 |
| 453 | no-disclosure | 1 |
| 454 | noeplasm | 1 |
| 455 | non-adenocarcinomas | 1 |
| 456 | non-evolution | 1 |
| 457 | non-inheritance | 1 |
| 458 | nonseparation | 1 |
| 459 | o-glycopeptides | 1 |
| 460 | obtundance | 1 |
| 461 | okhotsk | 1 |
| 462 | order/type | 1 |
| 463 | orthographs | 1 |
| 464 | outpatient-clinics | 1 |
| 465 | over-mediatization | 1 |
| 466 | overextension | 1 |
| 467 | oversupression | 1 |
| 468 | ovulation-years | 1 |
| 469 | oxy-p450scc-ch | 1 |
| 470 | p-neomenthyloxyphenyl-tetra-zole | 1 |
| 471 | p-vin | 1 |
| 472 | p6-stimulation | 1 |
| 473 | pa-grading | 1 |
| 474 | paedaudiology | 1 |
| 475 | papuloerythroderma | 1 |
| 476 | parachordoma/myoepithelioma | 1 |
| 477 | parafunction | 1 |
| 478 | parasitologie | 1 |
| 479 | peat-humidity | 1 |
| 480 | personalized-recommendation | 1 |
| 481 | ph.a | 1 |
| 482 | pharmocogenetics | 1 |
| 483 | phasicity | 1 |
| 484 | phemomena | 1 |
| 485 | phenobabritone | 1 |
| 486 | phm-technologies | 1 |
| 487 | phn-pain | 1 |
| 488 | phosphoforms | 1 |
| 489 | photo-disassembly | 1 |
| 490 | phyto-supplements | 1 |
| 491 | pings | 1 |
| 492 | placebo/acarbose | 1 |
| 493 | platinum-docetaxel | 1 |
| 494 | plenitude | 1 |
| 495 | pneumonia/sepsis/exacerbation | 1 |
| 496 | polyglycosides | 1 |
| 497 | polymorphonuclears | 1 |
| 498 | polyphagy | 1 |
| 499 | positivity/overexpression | 1 |
| 500 | pparalpha/rxralpha | 1 |
| 501 | ppis-amoxicillin-metronidazole | 1 |
| 502 | prandoni | 1 |
| 503 | pravastatin/auc0-8 | 1 |
| 504 | prdps | 1 |
| 505 | propanol/kg | 1 |
| 506 | propionamides | 1 |
| 507 | proteinases-inhibitors | 1 |
| 508 | protothecosis | 1 |
| 509 | psk9 | 1 |
| 510 | ptsd.seven | 1 |
| 511 | puebla-panama | 1 |
| 512 | pyrazolopyrazines | 1 |
| 513 | questions-that | 1 |
| 514 | re-evaporation | 1 |
| 515 | re-oligotrophication | 1 |
| 516 | re-preparation | 1 |
| 517 | re-puncture | 1 |
| 518 | reception/time | 1 |
| 519 | recruitment-retention | 1 |
| 520 | recurrences/number | 1 |
| 521 | regaud | 1 |
| 522 | reintvervention | 1 |
| 523 | reoccurence | 1 |
| 524 | res/kg | 1 |
| 525 | research/avoidance | 1 |
| 526 | restraint/disinhibition | 1 |
| 527 | results.meta-analysis | 1 |
| 528 | rls-patients | 1 |
| 529 | rmeta | 1 |
| 530 | root-nodules | 1 |
| 531 | rpl26-snr49 | 1 |
| 532 | rs657152 | 1 |
| 533 | rsfis | 1 |
| 534 | rtial2 | 1 |
| 535 | sareito | 1 |
| 536 | screening-assessment | 1 |
| 537 | sediment/encrustation | 1 |
| 538 | sedt8 | 1 |
| 539 | self-adequacy | 1 |
| 540 | self-eating | 1 |
| 541 | self-shielding | 1 |
| 542 | self-tanners | 1 |
| 543 | semistarvation | 1 |
| 544 | serviceman | 1 |
| 545 | sham-operations | 1 |
| 546 | shengmei | 1 |
| 547 | shock-loading | 1 |
| 548 | signal-network | 1 |
| 549 | significativeness | 1 |
| 550 | sixteen-sessions | 1 |
| 551 | smfeo3 | 1 |
| 552 | spores/gram | 1 |
| 553 | spp+st | 1 |
| 554 | star99 | 1 |
| 555 | stibased | 1 |
| 556 | stopit-2 | 1 |
| 557 | striping | 1 |
| 558 | stroids | 1 |
| 559 | study/strain | 1 |
| 560 | success-confidence | 1 |
| 561 | success.it | 1 |
| 562 | sucrose/acarbose | 1 |
| 563 | suprabioavailability | 1 |
| 564 | surgeons/association | 1 |
| 565 | susceptibility/infection | 1 |
| 566 | swb-that | 1 |
| 567 | sycloferon | 1 |
| 568 | sympathomodulation | 1 |
| 569 | symptoms-onset | 1 |
| 570 | table-egg-layers | 1 |
| 571 | tandem-only | 1 |
| 572 | tarakeswar | 1 |
| 573 | taster-status | 1 |
| 574 | theagency | 1 |
| 575 | therapy/failure | 1 |
| 576 | thermo-stress | 1 |
| 577 | thesphonation | 1 |
| 578 | thickener/stabilizer | 1 |
| 579 | time-on-stream | 1 |
| 580 | timing/type | 1 |
| 581 | tiresomeness | 1 |
| 582 | tools-instruments | 1 |
| 583 | tradenames | 1 |
| 584 | transcytosis/transmission | 1 |
| 585 | treatment/last | 1 |
| 586 | trichlorfon/kg | 1 |
| 587 | trichomonosomycosis | 1 |
| 588 | tsaa/kg | 1 |
| 589 | tsirulnikov | 1 |
| 590 | twelve-point | 1 |
| 591 | ulysses | 1 |
| 592 | underrunning | 1 |
| 593 | understudying | 1 |
| 594 | underwrapping | 1 |
| 595 | uretero-neocystostomy | 1 |
| 596 | use/convenience | 1 |
| 597 | userfriendliness | 1 |
| 598 | vaccine-protection | 1 |
| 599 | vaporing | 1 |
| 600 | varenciline | 1 |
| 601 | varicocèle | 1 |
| 602 | vc/kg | 1 |
| 603 | vericocelectomy | 1 |
| 604 | voice-treatment | 1 |
| 605 | v˙2max | 1 |
| 606 | water/day | 1 |
| 607 | wm/kg | 1 |
| 608 | wz/zb | 1 |
| 609 | xylf | 1 |
| 610 | yp/kg | 1 |
| 611 | α-radiolysis | 1 |
| 612 | ∼90° | 1 |
| 613 | ≤4/5 | 1 |
| 614 | ≥0.2mmol/kg | 1 |
| 615 | ≥6/10 | 1 |
| 616 | ≥pr | 1 |
| 1 | 'clearance | 1 |
| 2 | 'schemas | 1 |
| 3 | /diagnosis | 1 |
| 4 | 0.030/cm3 | 1 |
| 5 | 0.05mg/g | 1 |
| 6 | 0.076-7.6ng/ml | 1 |
| 7 | 0.1-1mg | 1 |
| 8 | 0.15g/l | 1 |
| 9 | 0.2491 | 1 |
| 10 | 0.521μg | 1 |
| 11 | 0.54/specificity | 1 |
| 12 | 0.590.validation | 1 |
| 13 | 0.5ml/min | 1 |
| 14 | 0.78:1 | 1 |
| 15 | 1,3-cyclohexadiones | 1 |
| 16 | 1,4-benzodiazepines | 1 |
| 17 | 1-32ng/ml | 1 |
| 18 | 1-me-d-trp | 1 |
| 19 | 1.26w/g | 1 |
| 20 | 1.5ml | 1 |
| 21 | 1.6g/d | 1 |
| 22 | 1/9-th | 1 |
| 23 | 10,000u | 1 |
| 24 | 1000uh | 1 |
| 25 | 11cycles | 1 |
| 26 | 11q13q21 | 1 |
| 27 | 12l/g | 1 |
| 28 | 13,328 | 1 |
| 29 | 14c-hdl | 1 |
| 30 | 17-hydroxycorticoids | 1 |
| 31 | 17β-reduction | 1 |
| 32 | 1mg/g | 1 |
| 33 | 2,720 | 1 |
| 34 | 2,992 | 1 |
| 35 | 2-fluorobenzaldehyde | 1 |
| 36 | 2.3/5 | 1 |
| 37 | 214.6-384.8mbq | 1 |
| 38 | 26.4±3.1 | 1 |
| 39 | 27-oh | 2 |
| 40 | 299g/kg | 1 |
| 41 | 3,7-β-o-diglucosides | 1 |
| 42 | 3-aryloxindoles | 2 |
| 43 | 3-br-pa | 1 |
| 44 | 3-halo-derivatives | 1 |
| 45 | 3-methyl-1-phenylpyrazole | 1 |
| 46 | 3-methylcarbazoles | 1 |
| 47 | 3.92ev | 1 |
| 48 | 30g/day | 1 |
| 49 | 30iu | 1 |
| 50 | 35ml/kg/h | 1 |
| 51 | 3d-crt/imrt | 1 |
| 52 | 3d-imaging | 3 |
| 53 | 3d-motion | 1 |
| 54 | 4-chloro-6-methyl | 1 |
| 55 | 4.2μm | 2 |
| 56 | 4.6-1.52 | 1 |
| 57 | 4.76±0.44 | 1 |
| 58 | 42-months | 1 |
| 59 | 43g | 1 |
| 60 | 46nt | 1 |
| 61 | 5'-deletions | 2 |
| 62 | 5-cis-lycopene | 1 |
| 63 | 5.3g | 1 |
| 64 | 50p/unit | 1 |
| 65 | 532~nm | 1 |
| 66 | 5`utr | 1 |
| 67 | 5months | 4 |
| 68 | 6-cycles | 1 |
| 69 | 78gy | 1 |
| 70 | 7s/kg | 2 |
| 71 | 8,14-dihydroxy-efv | 1 |
| 72 | 8-sessions | 2 |
| 73 | 80±21g | 1 |
| 74 | 90°c/h | 1 |
| 75 | 92.3kg | 1 |
| 76 | aa21-40aa141-160 | 1 |
| 77 | aas-use | 2 |
| 78 | abruptness | 1 |
| 79 | accordances | 1 |
| 80 | actg076 | 1 |
| 81 | action | 12,158 |
| 82 | action-antagonism | 1 |
| 83 | action-restoration | 1 |
| 84 | activation/duration | 1 |
| 85 | active-site-cyssh | 1 |
| 86 | activty | 2 |
| 87 | acwy-tt+mmrv | 2 |
| 88 | adequate-duration | 1 |
| 89 | administration/management | 1 |
| 90 | age-effect | 1 |
| 91 | age.meta-analysis | 1 |
| 92 | ahistory | 1 |
| 93 | ai-use | 1 |
| 94 | ailin | 1 |
| 95 | air-sampling | 1 |
| 96 | al/ca | 2 |
| 97 | ala-272 | 1 |
| 98 | albumin/l | 1 |
| 99 | alginate/calcium | 1 |
| 100 | alhavi | 4 |
| 101 | alkylglycerols | 2 |
| 102 | allopurinol/kg | 2 |
| 103 | allspice/kg | 1 |
| 104 | ampliation | 1 |
| 105 | ampula | 1 |
| 106 | angiomyxoma | 3 |
| 107 | anxyolitics | 1 |
| 108 | as-fast-as-you-can | 1 |
| 109 | asparaginate | 2 |
| 110 | ast/kg | 3 |
| 111 | asylum | 40 |
| 112 | atheroregression | 1 |
| 113 | attachment/detachment | 1 |
| 114 | attestation | 1 |
| 115 | autism-or | 1 |
| 116 | autoflora | 1 |
| 117 | baceo3 | 3 |
| 118 | bacteria/l | 1 |
| 119 | baicalin+berberine | 1 |
| 120 | baromemteosensivity | 1 |
| 121 | base-stocks | 1 |
| 122 | bb1-10 | 1 |
| 123 | bb1-4 | 1 |
| 124 | bb3-12 | 1 |
| 125 | bep-treatment | 1 |
| 126 | beta-mangostin | 1 |
| 127 | bevacizumab/5-fu/lv | 1 |
| 128 | bi-nucleation | 1 |
| 129 | bi-products | 1 |
| 130 | bias.meta-analysis | 1 |
| 131 | bias.none | 2 |
| 132 | bias.quality | 1 |
| 133 | bias.studies | 1 |
| 134 | binding-release | 1 |
| 135 | bio-responses | 2 |
| 136 | biodisesl | 1 |
| 137 | biogenicity | 1 |
| 138 | bioisosters | 1 |
| 139 | bisphosphontes | 1 |
| 140 | bleomycine | 2 |
| 141 | blinding.none | 1 |
| 142 | bortezomib-mp | 1 |
| 143 | bowstring | 1 |
| 144 | ca/kg | 8 |
| 145 | ca2+/atpase | 1 |
| 146 | cafu/kg | 1 |
| 147 | calliphorinae | 1 |
| 148 | cancer-quality | 6 |
| 149 | capecitabine/rt | 1 |
| 150 | carabanchel | 1 |
| 151 | care/types | 1 |
| 152 | casemanagement | 1 |
| 153 | cd45ra/ccr7 | 1 |
| 154 | cdsss/kmss | 7 |
| 155 | chemoprotectants | 6 |
| 156 | chicory/ton | 1 |
| 157 | chlorambucil-rituximab | 1 |
| 158 | chlortetracycline/kg | 1 |
| 159 | cholecysto-choledocholi-thiasis | 1 |
| 160 | chronomedicine | 6 |
| 161 | cinocardioangiograms | 1 |
| 162 | ciprofloxacin-tinidazole | 1 |
| 163 | cisplatin/m2 | 1 |
| 164 | co2-baths | 3 |
| 165 | cocarettes | 1 |
| 166 | cocoa-flavanols | 1 |
| 167 | cocoa/chocolate | 1 |
| 168 | coevolution | 20 |
| 169 | coextraction | 1 |
| 170 | coffins | 2 |
| 171 | cografting | 1 |
| 172 | colonizaion | 1 |
| 173 | coloproctology | 15 |
| 174 | complications.comparison | 2 |
| 175 | concretes | 1 |
| 176 | constipation-quality | 4 |
| 177 | consulting-cum-dispensing | 1 |
| 178 | corn/kg | 1 |
| 179 | corticorteroids | 1 |
| 180 | corticosteroides | 1 |
| 181 | cpimpdh·imp·8k | 1 |
| 182 | cr-c60 | 1 |
| 183 | cr/kg | 9 |
| 184 | cranberry-proanthocyandins | 2 |
| 185 | crmn/ctm | 1 |
| 186 | cross-bracing | 1 |
| 187 | crotonaldehyde/kg | 1 |
| 188 | crowders | 1 |
| 189 | ct/kg | 1 |
| 190 | cuspules | 1 |
| 191 | cys-40 | 1 |
| 192 | d-isomeres | 1 |
| 193 | dads/kg | 1 |
| 194 | darwinism | 1 |
| 195 | de-icing | 1 |
| 196 | deagglomeration | 1 |
| 197 | decelerator/extensor | 1 |
| 198 | dehiscence/necrosis | 1 |
| 199 | demands/deliveries | 1 |
| 200 | demicellization | 6 |
| 201 | demophobia | 1 |
| 202 | dhule | 1 |
| 203 | di-allyl-ation | 1 |
| 204 | diachrome/kg | 1 |
| 205 | dialysis.this | 1 |
| 206 | diatrofen | 1 |
| 207 | dihydrobenzothiepinones | 1 |
| 208 | diveticula | 1 |
| 209 | dmpa-subcutaneous | 1 |
| 210 | dosrs-dost/devrs-rv2027c | 2 |
| 211 | drug-sparing | 2 |
| 212 | duration/frequency | 1 |
| 213 | dys-synchronization | 1 |
| 214 | e-liquids/e-juices | 1 |
| 215 | e2-cypionate | 1 |
| 216 | ecg/bnp | 1 |
| 217 | ectomycorrhizae | 1 |
| 218 | effect.we | 3 |
| 219 | egcg/kg | 1 |
| 220 | egfr/erbb2 | 1 |
| 221 | electro-pathophysiology | 1 |
| 222 | embriopathy | 1 |
| 223 | eml1 | 1 |
| 224 | enchantment | 1 |
| 225 | endothermy | 1 |
| 226 | ensurance | 1 |
| 227 | enzyme/g | 1 |
| 228 | enzyme/kg | 2 |
| 229 | ep-cam-expression | 2 |
| 230 | epidydimitis | 1 |
| 231 | epilepsy/absence | 1 |
| 232 | erythromycylamine | 1 |
| 233 | escorts | 4 |
| 234 | estrification | 1 |
| 235 | estrogen/er | 1 |
| 236 | etoposide/m2 | 1 |
| 237 | evidence/opinion | 1 |
| 238 | evolutionism | 3 |
| 239 | exceedences | 1 |
| 240 | eximerization | 1 |
| 241 | expectancy-manipulation | 1 |
| 242 | exposure-that | 1 |
| 243 | extracts.based | 1 |
| 244 | falkenberg | 1 |
| 245 | falling.there | 1 |
| 246 | falls.eighteen | 1 |
| 247 | fdft1 | 1 |
| 248 | fear-relevance | 3 |
| 249 | fever≥38.0°c | 1 |
| 250 | fexofenadine.this | 1 |
| 251 | fine-groupings | 1 |
| 252 | flight/time | 1 |
| 253 | fluid-responsiveness | 1 |
| 254 | fluid/vapor | 1 |
| 255 | fncs | 1 |
| 256 | follow-up.this | 2 |
| 257 | formation/disappearance | 1 |
| 258 | fpss | 5 |
| 259 | frewuency | 1 |
| 260 | friars | 1 |
| 261 | fruchaud | 1 |
| 262 | funding/conflict | 1 |
| 263 | gal021/placebo | 1 |
| 264 | gastro/duodenojejunostomy | 2 |
| 265 | genistein/kg | 1 |
| 266 | genistein•kg | 1 |
| 267 | genuineness | 3 |
| 268 | gh/igfs | 1 |
| 269 | giardisis | 1 |
| 270 | glp-2/kg | 1 |
| 271 | gpt2p | 3 |
| 272 | growth/day | 1 |
| 273 | guilt/lack | 1 |
| 274 | h-13 | 1 |
| 275 | hachimi-jio-gan/day/200g | 1 |
| 276 | half-metallicity | 5 |
| 277 | hav-igg | 1 |
| 278 | health-care-providers | 1 |
| 279 | heat-fire | 1 |
| 280 | heptamers | 1 |
| 281 | herbs-change | 1 |
| 282 | hesperidin/kg | 1 |
| 283 | hesperidin•kg | 1 |
| 284 | heterarchy | 1 |
| 285 | hexacarbonyl | 1 |
| 286 | high-grade/cancer | 1 |
| 287 | hippocampal-tnf | 1 |
| 288 | his337 | 1 |
| 289 | hiv-pis | 2 |
| 290 | homocysteinaemia | 1 |
| 291 | homogeny | 1 |
| 292 | hotter-than-normal | 1 |
| 293 | hsp20-overexpression | 1 |
| 294 | hunault | 1 |
| 295 | hymexozol | 1 |
| 296 | hyper-activity/hyper-synchrony | 1 |
| 297 | hyperadrenergism | 1 |
| 298 | hyperalgesia/length | 1 |
| 299 | hypertonocity | 1 |
| 300 | hypocholesterolaemia | 1 |
| 301 | hyposensitizations | 1 |
| 302 | id/ida | 1 |
| 303 | if-then | 14 |
| 304 | ifn-gamma1b | 2 |
| 305 | ignificance | 1 |
| 306 | iiia-cp/cpps | 1 |
| 307 | il-22/il-34 | 1 |
| 308 | ilkpa | 1 |
| 309 | ill-treatment | 1 |
| 310 | immunoreceptors | 2 |
| 311 | implementation.direction | 1 |
| 312 | imprecision.two | 1 |
| 313 | incursions | 2 |
| 314 | inducers/inhibitors | 1 |
| 315 | infection-three | 1 |
| 316 | infectons | 1 |
| 317 | inhalation-technique | 1 |
| 318 | inner-accumulation | 1 |
| 319 | inputs-mechanism-outputs | 1 |
| 320 | interfusion | 1 |
| 321 | interim-analysis | 2 |
| 322 | intersexuality | 2 |
| 323 | intraklassen-correlations | 1 |
| 324 | inverse-weighting | 1 |
| 325 | influence | 1 |
| 326 | ipsrt-regulation | 1 |
| 327 | iridologists | 2 |
| 328 | iso-effectivity | 1 |
| 329 | isogeny | 1 |
| 330 | isolation/industrialization | 1 |
| 331 | it.it | 1 |
| 332 | jiayou | 1 |
| 333 | joven | 2 |
| 334 | jukovsky | 1 |
| 335 | kr23 | 1 |
| 336 | lactonazole | 1 |
| 337 | lbw242 | 2 |
| 338 | ldl-c-reduction | 1 |
| 339 | leaded-petrol | 1 |
| 340 | leucophores | 3 |
| 341 | life.all | 1 |
| 342 | life.most | 1 |
| 343 | life/activities | 1 |
| 344 | ligation/division | 1 |
| 345 | light-dependence | 1 |
| 346 | limb-loss | 2 |
| 347 | livopo4 | 3 |
| 348 | load-volume | 1 |
| 349 | louvain | 1 |
| 350 | lp229v | 1 |
| 351 | lps/kg | 2 |
| 352 | macrocyclizations | 1 |
| 353 | manualisation | 1 |
| 354 | masculinities | 9 |
| 355 | massage/aromatherapy | 2 |
| 356 | mechanization | 3 |
| 357 | melamine/kg | 1 |
| 358 | metallo-enzymes | 2 |
| 359 | methylphenidate/placebo | 1 |
| 360 | mg2+/kg | 2 |
| 361 | mg277 | 1 |
| 362 | micro-foci | 2 |
| 363 | micro-veins | 1 |
| 364 | microagglutination | 1 |
| 365 | microinjuries | 1 |
| 366 | microvacuoles | 3 |
| 367 | mir-124-5p | 1 |
| 368 | mir-124a | 7 |
| 369 | mir-7a | 1 |
| 370 | miscegenation | 1 |
| 371 | misdetections | 1 |
| 372 | mono-instead | 1 |
| 373 | monothio-1,3-diketones | 1 |
| 374 | moralization | 11 |
| 375 | morphine+50mg | 1 |
| 376 | mpt/mps | 1 |
| 377 | mri-features | 1 |
| 378 | multi-data | 1 |
| 379 | multidifferentiation | 3 |
| 380 | multitudiness | 1 |
| 381 | mutagenesity | 1 |
| 382 | mvc1 | 1 |
| 383 | mxcxxc | 1 |
| 384 | n-disubstituents | 1 |
| 385 | nad3 | 1 |
| 386 | nano-scaling | 4 |
| 387 | nanopesticides | 4 |
| 388 | natriuria | 1 |
| 389 | nbcl5 | 1 |
| 390 | needles/dislike | 1 |
| 391 | neuexin-3 | 1 |
| 392 | news-impact | 1 |
| 393 | nh3/min/mg | 1 |
| 394 | nile-delta | 1 |
| 395 | nitrites/g | 1 |
| 396 | no-disclosure | 1 |
| 397 | noeplasm | 1 |
| 398 | non-adenocarcinomas | 1 |
| 399 | non-cessation | 4 |
| 400 | non-comparability | 2 |
| 401 | non-evolution | 1 |
| 402 | non-inheritance | 1 |
| 403 | nondiagnosis | 3 |
| 404 | nonlocality | 2 |
| 405 | nonseparation | 1 |
| 406 | o-glycopeptides | 1 |
| 407 | obstruction/reflux | 2 |
| 408 | obtundance | 1 |
| 409 | okhotsk | 1 |
| 410 | order/type | 1 |
| 411 | orthographs | 1 |
| 412 | outpatient-clinics | 1 |
| 413 | over-inhibition | 2 |
| 414 | over-mediatization | 1 |
| 415 | overextension | 1 |
| 416 | oversupression | 1 |
| 417 | ovulation-years | 1 |
| 418 | oxy-p450scc-ch | 1 |
| 419 | p-neomenthyloxyphenyl-tetra-zole | 1 |
| 420 | p-vin | 1 |
| 421 | p6-stimulation | 1 |
| 422 | pa-grading | 1 |
| 423 | paedaudiology | 1 |
| 424 | papuloerythroderma | 1 |
| 425 | parachordoma/myoepithelioma | 1 |
| 426 | parafunction | 1 |
| 427 | parasitologie | 1 |
| 428 | partograms | 4 |
| 429 | peat-humidity | 1 |
| 430 | personalized-recommendation | 1 |
| 431 | pf-3893787 | 3 |
| 432 | ph.a | 1 |
| 433 | pharmocogenetics | 1 |
| 434 | phasicity | 1 |
| 435 | phemomena | 1 |
| 436 | phenobabritone | 1 |
| 437 | phip/μmol | 3 |
| 438 | phm-technologies | 1 |
| 439 | phn-pain | 1 |
| 440 | phosphoforms | 1 |
| 441 | photo-disassembly | 1 |
| 442 | photopenia | 2 |
| 443 | phyto-supplements | 1 |
| 444 | pings | 1 |
| 445 | placebo/acarbose | 1 |
| 446 | platinum-docetaxel | 1 |
| 447 | pleiotropy | 25 |
| 448 | plenitude | 1 |
| 449 | pneumonia/sepsis/exacerbation | 1 |
| 450 | polyglycosides | 1 |
| 451 | polymorphonuclears | 1 |
| 452 | polyphagy | 1 |
| 453 | positivity/overexpression | 1 |
| 454 | pparalpha/rxralpha | 1 |
| 455 | ppis-amoxicillin-metronidazole | 1 |
| 456 | prandoni | 1 |
| 457 | pravastatin/auc0-8 | 1 |
| 458 | prdps | 1 |
| 459 | products/procedures | 2 |
| 460 | professionalization | 8 |
| 461 | propanol/kg | 1 |
| 462 | propionamides | 1 |
| 463 | proteinases-inhibitors | 1 |
| 464 | protothecosis | 1 |
| 465 | psk9 | 1 |
| 466 | ptsd.seven | 1 |
| 467 | puebla-panama | 1 |
| 468 | punch-biopsies | 2 |
| 469 | pyrazolones | 2 |
| 470 | pyrazolopyrazines | 1 |
| 471 | quercetin/kg | 2 |
| 472 | questions-that | 1 |
| 473 | radicalism | 2 |
| 474 | re-evaporation | 1 |
| 475 | re-oligotrophication | 1 |
| 476 | re-preparation | 1 |
| 477 | re-puncture | 1 |
| 478 | re-referrals | 2 |
| 479 | rebate | 4 |
| 480 | receiver/stimulator | 2 |
| 481 | reception/time | 1 |
| 482 | recitations | 2 |
| 483 | recruitment-retention | 1 |
| 484 | recurrences/number | 1 |
| 485 | regaud | 1 |
| 486 | reintvervention | 1 |
| 487 | removal-area | 2 |
| 488 | reoccurence | 1 |
| 489 | res/kg | 1 |
| 490 | research/avoidance | 1 |
| 491 | restraint/disinhibition | 1 |
| 492 | results.meta-analysis | 1 |
| 493 | revenue-generating | 2 |
| 494 | rls-patients | 1 |
| 495 | rmeta | 1 |
| 496 | ro4607381 | 3 |
| 497 | root-nodules | 1 |
| 498 | rpl-1980 | 2 |
| 499 | rpl26-snr49 | 1 |
| 500 | rrss | 3 |
| 501 | rs657152 | 1 |
| 502 | rsfis | 1 |
| 503 | rtial2 | 1 |
| 504 | sareito | 1 |
| 505 | sb90-70 | 2 |
| 506 | science/web | 2 |
| 507 | screening-assessment | 1 |
| 508 | sediment/encrustation | 1 |
| 509 | sedt8 | 1 |
| 510 | self-adequacy | 1 |
| 511 | self-complexity | 5 |
| 512 | self-eating | 1 |
| 513 | self-estimates | 7 |
| 514 | self-handicapping | 8 |
| 515 | self-potentiation | 2 |
| 516 | self-shielding | 1 |
| 517 | self-tanners | 1 |
| 518 | semistarvation | 1 |
| 519 | serviceman | 1 |
| 520 | sham-operations | 1 |
| 521 | shengmei | 1 |
| 522 | shock-loading | 1 |
| 523 | shreds | 2 |
| 524 | signal-network | 1 |
| 525 | significativeness | 1 |
| 526 | single-myoma-removal | 2 |
| 527 | sixteen-sessions | 1 |
| 528 | smfeo3 | 1 |
| 529 | spliced-mrna | 2 |
| 530 | spores/gram | 1 |
| 531 | spp+st | 1 |
| 532 | star99 | 1 |
| 533 | stibased | 1 |
| 534 | stopit-2 | 1 |
| 535 | striping | 1 |
| 536 | stroids | 1 |
| 537 | study/strain | 1 |
| 538 | success-confidence | 1 |
| 539 | success.it | 1 |
| 540 | successors | 8 |
| 541 | sucram/t | 5 |
| 542 | sucrose/acarbose | 1 |
| 543 | super-hydration | 3 |
| 544 | suprabioavailability | 1 |
| 545 | surgeons/association | 1 |
| 546 | susceptibility/infection | 1 |
| 547 | swb-that | 1 |
| 548 | swiftlets | 2 |
| 549 | sycloferon | 1 |
| 550 | sympathomodulation | 1 |
| 551 | symptoms-onset | 1 |
| 552 | table-egg-layers | 1 |
| 553 | tandem-only | 1 |
| 554 | tarakeswar | 1 |
| 555 | taster-status | 1 |
| 556 | test-treat | 5 |
| 557 | tetrahydropteridines | 2 |
| 558 | th2-cytokines | 2 |
| 559 | theagency | 1 |
| 560 | therapy/failure | 1 |
| 561 | thereto | 2 |
| 562 | thermo-stress | 1 |
| 563 | thesphonation | 1 |
| 564 | thickener/stabilizer | 1 |
| 565 | thr/kg | 3 |
| 566 | time-on-stream | 1 |
| 567 | timing/type | 1 |
| 568 | tiresomeness | 1 |
| 569 | tonifying-kidney | 3 |
| 570 | tools-instruments | 1 |
| 571 | tradenames | 1 |
| 572 | tralpha1 | 4 |
| 573 | transcytosis/transmission | 1 |
| 574 | treatment/last | 1 |
| 575 | tremors/shaking | 2 |
| 576 | triamcinolone-bevacizumab | 2 |
| 577 | trichlorfon/kg | 1 |
| 578 | trichomonosomycosis | 1 |
| 579 | tsaa/kg | 1 |
| 580 | tsirulnikov | 1 |
| 581 | twelve-point | 1 |
| 582 | ulysses | 1 |
| 583 | unc-45b | 3 |
| 584 | underrunning | 1 |
| 585 | understudying | 1 |
| 586 | underwrapping | 1 |
| 587 | uretero-neocystostomy | 1 |
| 588 | use/convenience | 1 |
| 589 | userfriendliness | 1 |
| 590 | uv-tolerance | 2 |
| 591 | vabâ | 3 |
| 592 | vaccine-protection | 1 |
| 593 | vaporing | 1 |
| 594 | varenciline | 1 |
| 595 | varicocèle | 1 |
| 596 | vc/kg | 1 |
| 597 | vericocelectomy | 1 |
| 598 | voice-treatment | 1 |
| 599 | v˙2max | 1 |
| 600 | w-nps | 2 |
| 601 | water/day | 1 |
| 602 | wm/kg | 1 |
| 603 | wz/zb | 1 |
| 604 | xylf | 1 |
| 605 | y783 | 2 |
| 606 | year-of-publication | 2 |
| 607 | yp/kg | 1 |
| 608 | α'-martensite | 5 |
| 609 | α-radiolysis | 1 |
| 610 | δpepn | 2 |
| 611 | η≈0.35 | 2 |
| 612 | ∼90° | 1 |
| 613 | ≤4/5 | 1 |
| 614 | ≥0.2mmol/kg | 1 |
| 615 | ≥6/10 | 1 |
| 616 | ≥pr | 1 |
| 1 | bb1-10 | 1 |
| 2 | ≥6/10 | 1 |
| 3 | 2,720 | 1 |
| 4 | cys-40 | 1 |
| 5 | aa21-40aa141-160 | 1 |
| 6 | cr-c60 | 1 |
| 7 | sb90-70 | 2 |
| 8 | rpl-1980 | 2 |
| 9 | 26.4±3.1 | 1 |
| 10 | 11q13q21 | 1 |
| 11 | ro4607381 | 3 |
| 12 | 0.2491 | 1 |
| 13 | 0.78:1 | 1 |
| 14 | tralpha1 | 4 |
| 15 | mvc1 | 1 |
| 16 | eml1 | 1 |
| 17 | fdft1 | 1 |
| 18 | stopit-2 | 1 |
| 19 | bb3-12 | 1 |
| 20 | lbw242 | 2 |
| 21 | 4.6-1.52 | 1 |
| 22 | rs657152 | 1 |
| 23 | ala-272 | 1 |
| 24 | 2,992 | 1 |
| 25 | egfr/erbb2 | 1 |
| 26 | rtial2 | 1 |
| 27 | etoposide/m2 | 1 |
| 28 | cisplatin/m2 | 1 |
| 29 | neuexin-3 | 1 |
| 30 | h-13 | 1 |
| 31 | kr23 | 1 |
| 32 | y783 | 2 |
| 33 | nad3 | 1 |
| 34 | 0.030/cm3 | 1 |
| 35 | baceo3 | 3 |
| 36 | smfeo3 | 1 |
| 37 | bb1-4 | 1 |
| 38 | il-22/il-34 | 1 |
| 39 | 4.76±0.44 | 1 |
| 40 | livopo4 | 3 |
| 41 | 2.3/5 | 1 |
| 42 | ≤4/5 | 1 |
| 43 | η≈0.35 | 2 |
| 44 | nbcl5 | 1 |
| 45 | actg076 | 1 |
| 46 | his337 | 1 |
| 47 | mg277 | 1 |
| 48 | pf-3893787 | 3 |
| 49 | cd45ra/ccr7 | 1 |
| 50 | pravastatin/auc0-8 | 1 |
| 51 | 13,328 | 1 |
| 52 | sedt8 | 1 |
| 53 | rpl26-snr49 | 1 |
| 54 | star99 | 1 |
| 55 | psk9 | 1 |
| 56 | ph.a | 1 |
| 57 | mir-124a | 7 |
| 58 | mir-7a | 1 |
| 59 | al/ca | 2 |
| 60 | id/ida | 1 |
| 61 | removal-area | 2 |
| 62 | pparalpha/rxralpha | 1 |
| 63 | demophobia | 1 |
| 64 | hypocholesterolaemia | 1 |
| 65 | homocysteinaemia | 1 |
| 66 | photopenia | 2 |
| 67 | natriuria | 1 |
| 68 | diveticula | 1 |
| 69 | ampula | 1 |
| 70 | puebla-panama | 1 |
| 71 | parachordoma/myoepithelioma | 1 |
| 72 | angiomyxoma | 3 |
| 73 | papuloerythroderma | 1 |
| 74 | phemomena | 1 |
| 75 | spliced-mrna | 2 |
| 76 | 3-br-pa | 1 |
| 77 | ilkpa | 1 |
| 78 | autoflora | 1 |
| 79 | multi-data | 1 |
| 80 | rmeta | 1 |
| 81 | nile-delta | 1 |
| 82 | ifn-gamma1b | 2 |
| 83 | unc-45b | 3 |
| 84 | chlorambucil-rituximab | 1 |
| 85 | triamcinolone-bevacizumab | 2 |
| 86 | science/web | 2 |
| 87 | wz/zb | 1 |
| 88 | dosrs-dost/devrs-rv2027c | 2 |
| 89 | mxcxxc | 1 |
| 90 | fever≥38.0°c | 1 |
| 91 | 1.6g/d | 1 |
| 92 | mono-instead | 1 |
| 93 | extracts.based | 1 |
| 94 | stibased | 1 |
| 95 | regaud | 1 |
| 96 | fruchaud | 1 |
| 97 | calliphorinae | 1 |
| 98 | ectomycorrhizae | 1 |
| 99 | ignificance | 1 |
| 100 | research/avoidance | 1 |
| 101 | obtundance | 1 |
| 102 | 'clearance | 1 |
| 103 | formation/disappearance | 1 |
| 104 | uv-tolerance | 2 |
| 105 | ensurance | 1 |
| 106 | non-inheritance | 1 |
| 107 | fear-relevance | 3 |
| 108 | success-confidence | 1 |
| 109 | light-dependence | 1 |
| 110 | use/convenience | 1 |
| 111 | reoccurence | 1 |
| 112 | epilepsy/absence | 1 |
| 113 | influence | 1 |
| 114 | plenitude | 1 |
| 115 | 2-fluorobenzaldehyde | 1 |
| 116 | infection-three | 1 |
| 117 | herbs-change | 1 |
| 118 | parasitologie | 1 |
| 119 | needles/dislike | 1 |
| 120 | p-neomenthyloxyphenyl-tetra-zole | 1 |
| 121 | ciprofloxacin-tinidazole | 1 |
| 122 | ppis-amoxicillin-metronidazole | 1 |
| 123 | lactonazole | 1 |
| 124 | 3-methyl-1-phenylpyrazole | 1 |
| 125 | dhule | 1 |
| 126 | varicocèle | 1 |
| 127 | reception/time | 1 |
| 128 | flight/time | 1 |
| 129 | load-volume | 1 |
| 130 | 5-cis-lycopene | 1 |
| 131 | chronomedicine | 6 |
| 132 | bleomycine | 2 |
| 133 | varenciline | 1 |
| 134 | erythromycylamine | 1 |
| 135 | baicalin+berberine | 1 |
| 136 | blinding.none | 1 |
| 137 | bias.none | 2 |
| 138 | phenobabritone | 1 |
| 139 | timing/type | 1 |
| 140 | order/type | 1 |
| 141 | falling.there | 1 |
| 142 | heat-fire | 1 |
| 143 | therapy/failure | 1 |
| 144 | no-disclosure | 1 |
| 145 | re-puncture | 1 |
| 146 | binding-release | 1 |
| 147 | ca2+/atpase | 1 |
| 148 | sucrose/acarbose | 1 |
| 149 | placebo/acarbose | 1 |
| 150 | ai-use | 1 |
| 151 | aas-use | 2 |
| 152 | rebate | 4 |
| 153 | cocoa/chocolate | 1 |
| 154 | asparaginate | 2 |
| 155 | e2-cypionate | 1 |
| 156 | α'-martensite | 5 |
| 157 | inhalation-technique | 1 |
| 158 | effect.we | 3 |
| 159 | xylf | 1 |
| 160 | hippocampal-tnf | 1 |
| 161 | enzyme/g | 1 |
| 162 | 1mg/g | 1 |
| 163 | 0.05mg/g | 1 |
| 164 | 12l/g | 1 |
| 165 | nitrites/g | 1 |
| 166 | 1.26w/g | 1 |
| 167 | hachimi-jio-gan/day/200g | 1 |
| 168 | 80±21g | 1 |
| 169 | 5.3g | 1 |
| 170 | 43g | 1 |
| 171 | hav-igg | 1 |
| 172 | mg2+/kg | 2 |
| 173 | glp-2/kg | 1 |
| 174 | tsaa/kg | 1 |
| 175 | ca/kg | 8 |
| 176 | vc/kg | 1 |
| 177 | allspice/kg | 1 |
| 178 | crotonaldehyde/kg | 1 |
| 179 | diachrome/kg | 1 |
| 180 | enzyme/kg | 2 |
| 181 | chlortetracycline/kg | 1 |
| 182 | melamine/kg | 1 |
| 183 | 299g/kg | 1 |
| 184 | egcg/kg | 1 |
| 185 | ≥0.2mmol/kg | 1 |
| 186 | propanol/kg | 1 |
| 187 | allopurinol/kg | 2 |
| 188 | wm/kg | 1 |
| 189 | hesperidin/kg | 1 |
| 190 | genistein/kg | 1 |
| 191 | quercetin/kg | 2 |
| 192 | trichlorfon/kg | 1 |
| 193 | corn/kg | 1 |
| 194 | yp/kg | 1 |
| 195 | cr/kg | 9 |
| 196 | thr/kg | 3 |
| 197 | 7s/kg | 2 |
| 198 | dads/kg | 1 |
| 199 | res/kg | 1 |
| 200 | lps/kg | 2 |
| 201 | ct/kg | 1 |
| 202 | ast/kg | 3 |
| 203 | cafu/kg | 1 |
| 204 | 92.3kg | 1 |
| 205 | hesperidin•kg | 1 |
| 206 | genistein•kg | 1 |
| 207 | nh3/min/mg | 1 |
| 208 | morphine+50mg | 1 |
| 209 | 0.1-1mg | 1 |
| 210 | cross-bracing | 1 |
| 211 | de-icing | 1 |
| 212 | shock-loading | 1 |
| 213 | pa-grading | 1 |
| 214 | self-shielding | 1 |
| 215 | 3d-imaging | 3 |
| 216 | tremors/shaking | 2 |
| 217 | nano-scaling | 4 |
| 218 | air-sampling | 1 |
| 219 | underrunning | 1 |
| 220 | striping | 1 |
| 221 | self-handicapping | 8 |
| 222 | underwrapping | 1 |
| 223 | drug-sparing | 2 |
| 224 | vaporing | 1 |
| 225 | bowstring | 1 |
| 226 | consulting-cum-dispensing | 1 |
| 227 | self-eating | 1 |
| 228 | revenue-generating | 2 |
| 229 | cografting | 1 |
| 230 | inverse-weighting | 1 |
| 231 | understudying | 1 |
| 232 | falkenberg | 1 |
| 233 | 0.521μg | 1 |
| 234 | 90°c/h | 1 |
| 235 | 35ml/kg/h | 1 |
| 236 | oxy-p450scc-ch | 1 |
| 237 | 27-oh | 2 |
| 238 | active-site-cyssh | 1 |
| 239 | 1/9-th | 1 |
| 240 | hyperalgesia/length | 1 |
| 241 | 1000uh | 1 |
| 242 | micro-foci | 2 |
| 243 | shengmei | 1 |
| 244 | prandoni | 1 |
| 245 | alhavi | 4 |
| 246 | cpimpdh·imp·8k | 1 |
| 247 | guilt/lack | 1 |
| 248 | signal-network | 1 |
| 249 | okhotsk | 1 |
| 250 | bacteria/l | 1 |
| 251 | 0.15g/l | 1 |
| 252 | albumin/l | 1 |
| 253 | hotter-than-normal | 1 |
| 254 | single-myoma-removal | 2 |
| 255 | 14c-hdl | 1 |
| 256 | carabanchel | 1 |
| 257 | platinum-docetaxel | 1 |
| 258 | life.all | 1 |
| 259 | 1-32ng/ml | 1 |
| 260 | 0.076-7.6ng/ml | 1 |
| 261 | 1.5ml | 1 |
| 262 | phip/μmol | 3 |
| 263 | leaded-petrol | 1 |
| 264 | hymexozol | 1 |
| 265 | biodisesl | 1 |
| 266 | 4-chloro-6-methyl | 1 |
| 267 | hexacarbonyl | 1 |
| 268 | time-on-stream | 1 |
| 269 | spores/gram | 1 |
| 270 | 532~nm | 1 |
| 271 | noeplasm | 1 |
| 272 | hyperadrenergism | 1 |
| 273 | radicalism | 2 |
| 274 | darwinism | 1 |
| 275 | action-antagonism | 1 |
| 276 | evolutionism | 3 |
| 277 | crmn/ctm | 1 |
| 278 | alginate/calcium | 1 |
| 279 | asylum | 40 |
| 280 | 4.2μm | 2 |
| 281 | as-fast-as-you-can | 1 |
| 282 | serviceman | 1 |
| 283 | falls.eighteen | 1 |
| 284 | diatrofen | 1 |
| 285 | if-then | 14 |
| 286 | ptsd.seven | 1 |
| 287 | joven | 2 |
| 288 | phn-pain | 1 |
| 289 | study/strain | 1 |
| 290 | louvain | 1 |
| 291 | ailin | 1 |
| 292 | 0.5ml/min | 1 |
| 293 | beta-mangostin | 1 |
| 294 | p-vin | 1 |
| 295 | colonizaion | 1 |
| 296 | evidence/opinion | 1 |
| 297 | ligation/division | 1 |
| 298 | overextension | 1 |
| 299 | atheroregression | 1 |
| 300 | oversupression | 1 |
| 301 | ep-cam-expression | 2 |
| 302 | hsp20-overexpression | 1 |
| 303 | positivity/overexpression | 1 |
| 304 | transcytosis/transmission | 1 |
| 305 | interfusion | 1 |
| 306 | di-allyl-ation | 1 |
| 307 | pneumonia/sepsis/exacerbation | 1 |
| 308 | estrification | 1 |
| 309 | re-oligotrophication | 1 |
| 310 | year-of-publication | 2 |
| 311 | 0.590.validation | 1 |
| 312 | personalized-recommendation | 1 |
| 313 | bi-nucleation | 1 |
| 314 | surgeons/association | 1 |
| 315 | ampliation | 1 |
| 316 | multidifferentiation | 3 |
| 317 | self-potentiation | 2 |
| 318 | sympathomodulation | 1 |
| 319 | ipsrt-regulation | 1 |
| 320 | p6-stimulation | 1 |
| 321 | inner-accumulation | 1 |
| 322 | expectancy-manipulation | 1 |
| 323 | miscegenation | 1 |
| 324 | microagglutination | 1 |
| 325 | thesphonation | 1 |
| 326 | re-preparation | 1 |
| 327 | nonseparation | 1 |
| 328 | super-hydration | 3 |
| 329 | deagglomeration | 1 |
| 330 | re-evaporation | 1 |
| 331 | action-restoration | 1 |
| 332 | adequate-duration | 1 |
| 333 | activation/duration | 1 |
| 334 | manualisation | 1 |
| 335 | non-cessation | 4 |
| 336 | attestation | 1 |
| 337 | sediment/encrustation | 1 |
| 338 | semistarvation | 1 |
| 339 | isolation/industrialization | 1 |
| 340 | professionalization | 8 |
| 341 | moralization | 11 |
| 342 | demicellization | 6 |
| 343 | mechanization | 3 |
| 344 | dys-synchronization | 1 |
| 345 | eximerization | 1 |
| 346 | over-mediatization | 1 |
| 347 | action | 12,158 |
| 348 | coextraction | 1 |
| 349 | susceptibility/infection | 1 |
| 350 | implementation.direction | 1 |
| 351 | vaccine-protection | 1 |
| 352 | parafunction | 1 |
| 353 | ldl-c-reduction | 1 |
| 354 | 17β-reduction | 1 |
| 355 | over-inhibition | 2 |
| 356 | restraint/disinhibition | 1 |
| 357 | recruitment-retention | 1 |
| 358 | reintvervention | 1 |
| 359 | 3d-motion | 1 |
| 360 | non-evolution | 1 |
| 361 | coevolution | 20 |
| 362 | sycloferon | 1 |
| 363 | complications.comparison | 2 |
| 364 | chicory/ton | 1 |
| 365 | δpepn | 2 |
| 366 | gal021/placebo | 1 |
| 367 | methylphenidate/placebo | 1 |
| 368 | thereto | 2 |
| 369 | sareito | 1 |
| 370 | imprecision.two | 1 |
| 371 | gpt2p | 3 |
| 372 | mir-124-5p | 1 |
| 373 | bortezomib-mp | 1 |
| 374 | ecg/bnp | 1 |
| 375 | 1-me-d-trp | 1 |
| 376 | 214.6-384.8mbq | 1 |
| 377 | tarakeswar | 1 |
| 378 | estrogen/er | 1 |
| 379 | recurrences/number | 1 |
| 380 | high-grade/cancer | 1 |
| 381 | thickener/stabilizer | 1 |
| 382 | autism-or | 1 |
| 383 | fluid/vapor | 1 |
| 384 | decelerator/extensor | 1 |
| 385 | receiver/stimulator | 2 |
| 386 | ≥pr | 1 |
| 387 | 5`utr | 1 |
| 388 | 'schemas | 1 |
| 389 | non-adenocarcinomas | 1 |
| 390 | outpatient-clinics | 1 |
| 391 | pharmocogenetics | 1 |
| 392 | anxyolitics | 1 |
| 393 | fncs | 1 |
| 394 | shreds | 2 |
| 395 | 17-hydroxycorticoids | 1 |
| 396 | corticorteroids | 1 |
| 397 | stroids | 1 |
| 398 | e-liquids/e-juices | 1 |
| 399 | accordances | 1 |
| 400 | exceedences | 1 |
| 401 | nanopesticides | 4 |
| 402 | propionamides | 1 |
| 403 | corticosteroides | 1 |
| 404 | 3,7-β-o-diglucosides | 1 |
| 405 | polyglycosides | 1 |
| 406 | o-glycopeptides | 1 |
| 407 | bias.studies | 1 |
| 408 | phm-technologies | 1 |
| 409 | demands/deliveries | 1 |
| 410 | microinjuries | 1 |
| 411 | punch-biopsies | 2 |
| 412 | masculinities | 9 |
| 413 | life/activities | 1 |
| 414 | 6-cycles | 1 |
| 415 | 11cycles | 1 |
| 416 | 3-aryloxindoles | 2 |
| 417 | microvacuoles | 3 |
| 418 | 3-methylcarbazoles | 1 |
| 419 | root-nodules | 1 |
| 420 | cuspules | 1 |
| 421 | tradenames | 1 |
| 422 | metallo-enzymes | 2 |
| 423 | tetrahydropteridines | 2 |
| 424 | th2-cytokines | 2 |
| 425 | 1,4-benzodiazepines | 1 |
| 426 | pyrazolopyrazines | 1 |
| 427 | 1,3-cyclohexadiones | 1 |
| 428 | pyrazolones | 2 |
| 429 | dihydrobenzothiepinones | 1 |
| 430 | monothio-1,3-diketones | 1 |
| 431 | care/types | 1 |
| 432 | d-isomeres | 1 |
| 433 | leucophores | 3 |
| 434 | products/procedures | 2 |
| 435 | mri-features | 1 |
| 436 | bio-responses | 2 |
| 437 | ulysses | 1 |
| 438 | self-estimates | 7 |
| 439 | concretes | 1 |
| 440 | bisphosphontes | 1 |
| 441 | cocarettes | 1 |
| 442 | 3-halo-derivatives | 1 |
| 443 | gh/igfs | 1 |
| 444 | pings | 1 |
| 445 | fine-groupings | 1 |
| 446 | orthographs | 1 |
| 447 | co2-baths | 3 |
| 448 | 42-months | 1 |
| 449 | 5months | 4 |
| 450 | rsfis | 1 |
| 451 | fexofenadine.this | 1 |
| 452 | follow-up.this | 2 |
| 453 | dialysis.this | 1 |
| 454 | hiv-pis | 2 |
| 455 | cholecysto-choledocholi-thiasis | 1 |
| 456 | giardisis | 1 |
| 457 | protothecosis | 1 |
| 458 | trichomonosomycosis | 1 |
| 459 | /diagnosis | 1 |
| 460 | nondiagnosis | 3 |
| 461 | dehiscence/necrosis | 1 |
| 462 | age.meta-analysis | 1 |
| 463 | bias.meta-analysis | 1 |
| 464 | results.meta-analysis | 1 |
| 465 | interim-analysis | 2 |
| 466 | α-radiolysis | 1 |
| 467 | epidydimitis | 1 |
| 468 | base-stocks | 1 |
| 469 | re-referrals | 2 |
| 470 | cocoa-flavanols | 1 |
| 471 | alkylglycerols | 2 |
| 472 | cinocardioangiograms | 1 |
| 473 | partograms | 4 |
| 474 | phosphoforms | 1 |
| 475 | cranberry-proanthocyandins | 2 |
| 476 | micro-veins | 1 |
| 477 | coffins | 2 |
| 478 | incursions | 2 |
| 479 | 8-sessions | 2 |
| 480 | sixteen-sessions | 1 |
| 481 | intraklassen-correlations | 1 |
| 482 | sham-operations | 1 |
| 483 | recitations | 2 |
| 484 | macrocyclizations | 1 |
| 485 | hyposensitizations | 1 |
| 486 | misdetections | 1 |
| 487 | 5'-deletions | 2 |
| 488 | infectons | 1 |
| 489 | prdps | 1 |
| 490 | mpt/mps | 1 |
| 491 | w-nps | 2 |
| 492 | iiia-cp/cpps | 1 |
| 493 | polymorphonuclears | 1 |
| 494 | ovulation-years | 1 |
| 495 | friars | 1 |
| 496 | health-care-providers | 1 |
| 497 | crowders | 1 |
| 498 | heptamers | 1 |
| 499 | self-tanners | 1 |
| 500 | bioisosters | 1 |
| 501 | table-egg-layers | 1 |
| 502 | successors | 8 |
| 503 | proteinases-inhibitors | 1 |
| 504 | inducers/inhibitors | 1 |
| 505 | immunoreceptors | 2 |
| 506 | tiresomeness | 1 |
| 507 | genuineness | 3 |
| 508 | fluid-responsiveness | 1 |
| 509 | significativeness | 1 |
| 510 | multitudiness | 1 |
| 511 | userfriendliness | 1 |
| 512 | abruptness | 1 |
| 513 | thermo-stress | 1 |
| 514 | cdsss/kmss | 7 |
| 515 | limb-loss | 2 |
| 516 | fpss | 5 |
| 517 | rrss | 3 |
| 518 | bi-products | 1 |
| 519 | swiftlets | 2 |
| 520 | chemoprotectants | 6 |
| 521 | rls-patients | 1 |
| 522 | phyto-supplements | 1 |
| 523 | tools-instruments | 1 |
| 524 | n-disubstituents | 1 |
| 525 | escorts | 4 |
| 526 | iridologists | 2 |
| 527 | inputs-mechanism-outputs | 1 |
| 528 | dmpa-subcutaneous | 1 |
| 529 | taster-status | 1 |
| 530 | sucram/t | 5 |
| 531 | test-treat | 5 |
| 532 | swb-that | 1 |
| 533 | exposure-that | 1 |
| 534 | questions-that | 1 |
| 535 | news-impact | 1 |
| 536 | age-effect | 1 |
| 537 | funding/conflict | 1 |
| 538 | symptoms-onset | 1 |
| 539 | success.it | 1 |
| 540 | it.it | 1 |
| 541 | 50p/unit | 1 |
| 542 | hunault | 1 |
| 543 | 46nt | 1 |
| 544 | administration/management | 1 |
| 545 | casemanagement | 1 |
| 546 | attachment/detachment | 1 |
| 547 | screening-assessment | 1 |
| 548 | voice-treatment | 1 |
| 549 | ill-treatment | 1 |
| 550 | bep-treatment | 1 |
| 551 | enchantment | 1 |
| 552 | twelve-point | 1 |
| 553 | capecitabine/rt | 1 |
| 554 | 3d-crt/imrt | 1 |
| 555 | spp+st | 1 |
| 556 | treatment/last | 1 |
| 557 | life.most | 1 |
| 558 | 10,000u | 1 |
| 559 | 30iu | 1 |
| 560 | jiayou | 1 |
| 561 | lp229v | 1 |
| 562 | 3.92ev | 1 |
| 563 | 8,14-dihydroxy-efv | 1 |
| 564 | bevacizumab/5-fu/lv | 1 |
| 565 | tsirulnikov | 1 |
| 566 | acwy-tt+mmrv | 2 |
| 567 | v˙2max | 1 |
| 568 | obstruction/reflux | 2 |
| 569 | 30g/day | 1 |
| 570 | growth/day | 1 |
| 571 | water/day | 1 |
| 572 | self-adequacy | 1 |
| 573 | theagency | 1 |
| 574 | duration/frequency | 1 |
| 575 | frewuency | 1 |
| 576 | tonifying-kidney | 3 |
| 577 | 78gy | 1 |
| 578 | polyphagy | 1 |
| 579 | paedaudiology | 1 |
| 580 | electro-pathophysiology | 1 |
| 581 | coloproctology | 15 |
| 582 | heterarchy | 1 |
| 583 | embriopathy | 1 |
| 584 | jukovsky | 1 |
| 585 | photo-disassembly | 1 |
| 586 | tandem-only | 1 |
| 587 | vericocelectomy | 1 |
| 588 | gastro/duodenojejunostomy | 2 |
| 589 | uretero-neocystostomy | 1 |
| 590 | endothermy | 1 |
| 591 | homogeny | 1 |
| 592 | isogeny | 1 |
| 593 | hyper-activity/hyper-synchrony | 1 |
| 594 | massage/aromatherapy | 2 |
| 595 | pleiotropy | 25 |
| 596 | ahistory | 1 |
| 597 | 0.54/specificity | 1 |
| 598 | half-metallicity | 5 |
| 599 | biogenicity | 1 |
| 600 | phasicity | 1 |
| 601 | hypertonocity | 1 |
| 602 | peat-humidity | 1 |
| 603 | nonlocality | 2 |
| 604 | constipation-quality | 4 |
| 605 | cancer-quality | 6 |
| 606 | bias.quality | 1 |
| 607 | intersexuality | 2 |
| 608 | suprabioavailability | 1 |
| 609 | non-comparability | 2 |
| 610 | mutagenesity | 1 |
| 611 | baromemteosensivity | 1 |
| 612 | iso-effectivity | 1 |
| 613 | self-complexity | 5 |
| 614 | activty | 2 |
| 615 | vabâ | 3 |
| 616 | ∼90° | 1 |